Multivalent Peptide Therapy for Neutrophil-Driven Skin Inflammation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neutrophil-driven inflammatory diseases such as atopic dermatitis and psoriasis are either ineffective or come with significant side effects, including immunosuppression and increased risk of infections and malignancies, necessitating a safer and more effective therapeutic approach.
Innovation Solution
Topical application of multivalent glutamine-containing peptides that serve as substrates for transglutaminases to cross-link corneocytes, restoring the skin barrier, combined with immune cell activation using CD301b+ macrophage-targeting ligands to eliminate inflammatory cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If topical corticosteroids and immunosuppressive drugs are used to treat neutrophil-driven inflammatory diseases, then inflammation is reduced, but the risk of infections and malignancies increases
Solution Approach 1:
The invention extracts and targets the specific pathological mechanism of neutrophil-driven inflammation, using peptides that selectively modulate neutrophil activity and skin barrier function without broad immunosuppression. The peptide compositions specifically address the inflammatory pathway while preserving overall immune function.
Solution Approach 2:
The patent uses peptide compositions as intermediary substances that mediate between the skin barrier and immune response. These peptides act as signaling molecules that restore barrier function and modulate inflammation through natural physiological pathways, avoiding the need for potent immunosuppressive drugs.
2Object-affected harmful factors
If JAK inhibitors are used as topical or oral formulations, then eczema symptoms improve in 40-50% of patients, but immunosuppression and side effects occur
Solution Approach 1:
The invention employs short-lived peptide molecules that are rapidly degraded after exerting their therapeutic effect. These peptides provide transient, localized action at the skin surface without accumulating systemically, thereby avoiding long-term immunosuppression and associated malignancy risks.
Solution Approach 2:
The patent changes the therapeutic parameter from systemic immunosuppression to localized peptide-mediated barrier restoration. By altering the mode of action from broad immunomodulation to specific skin barrier repair, the treatment achieves efficacy without the harmful systemic effects of JAK inhibitors.
3Object-affected harmful factors
If dupilumab is administered to treat moderate-to-severe eczema, then inflammation is subduced, but conjunctivitis and other side effects occur
Solution Approach 1:
The invention applies local quality by delivering peptide compositions specifically to the skin surface where they act locally to restore barrier function and reduce inflammation. This localized action avoids systemic circulation and prevents off-target effects such as conjunctivitis that occur with systemic biologics like dupilumab.
4Object-affected harmful factors
If current treatments are used, then some symptom improvement is achieved, but treatment costs and logistics become significant
Solution Approach 1:
The patent employs inexpensive peptide compositions that can be manufactured at low cost and applied topically without complex delivery systems. These disposable peptide applications eliminate the need for expensive monoclonal antibodies and complex injection logistics, making treatment accessible and scalable.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Rapid restoration of skin barrier function and reduced inflammation without adverse effects, offering a low-cost, non-toxic treatment option with potential synergistic benefits when combined with existing drugs.
Implementation Method 1
multivalent glutamine-containing peptides that serve as substrates for transglutaminases to cross-link corneocytes
Implementation Method 2
substrates for transglutaminases to cross-link corneocytes
Implementation Method 3
CD301b+ macrophages in the dermis are also activated to phagocytize and remove residual neutrophils
Data Source
AI summary
The present invention provides a method of treating pathological inflammation in a patient comprising: administering to the patient a multivalent structured polypeptide comprising at least one therapeutic peptide. The present invention also provides a kit, comprising: a multivalent structured polypeptide comprising at least one therapeutic peptide; and instructions teaching administration of the multivalent structured polypeptide to a patient having atopic dermatitis.